Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. (SHE:301584)
China · Delayed Price · Currency is CNY 18.53
+0.60 (3.35%)
At close: Sep 30, 2026
SHE:301584 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,806 | 12,310 | - | - | - | - | |
Market Cap Growth | -45.69% | - | - | - | - | - |
Enterprise Value | 10,105 | 14,622 | - | - | - | - |
Last Close Price | 18.53 | 28.82 | - | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.99 | 45.66 | - | - | - | - |
PS Ratio | 0.40 | 0.63 | - | - | - | - |
PB Ratio | 3.09 | 5.00 | - | - | - | - |
P/TBV Ratio | 3.68 | 5.93 | - | - | - | - |
P/FCF Ratio | 8.24 | 18.44 | - | - | - | - |
P/OCF Ratio | 7.64 | 16.45 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.52 | 0.75 | - | - | - | - |
EV/EBITDA Ratio | 14.88 | 23.59 | - | - | - | - |
EV/EBIT Ratio | 17.20 | 25.23 | - | - | - | - |
EV/FCF Ratio | 10.67 | 21.90 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.40 | 1.46 | 2.28 | 2.56 | 2.23 | 1.33 |
Debt / EBITDA Ratio | 5.20 | 5.36 | 6.46 | 7.31 | 7.05 | 4.55 |
Debt / FCF Ratio | 3.73 | 5.37 | 93.13 | - | - | - |
Net Debt / Equity Ratio | 0.77 | 0.67 | 1.27 | 1.52 | 1.31 | 0.75 |
Net Debt / EBITDA Ratio | 3.08 | 2.68 | 3.94 | 4.75 | 4.57 | 2.80 |
Net Debt / FCF Ratio | 2.05 | 2.49 | 51.95 | -4.76 | -2.27 | -1.00 |
Asset Turnover | - | 1.40 | 1.48 | 1.53 | 1.43 | 1.37 |
Inventory Turnover | - | 5.18 | 5.54 | 6.55 | 7.16 | 10.86 |
Quick Ratio | 0.84 | 0.83 | 0.76 | 0.81 | 0.84 | 0.88 |
Current Ratio | 1.17 | 1.16 | 1.12 | 1.12 | 1.13 | 1.14 |
Return on Equity (ROE) | 16.68% | 15.81% | 17.07% | 17.63% | 17.72% | 15.74% |
Return on Assets (ROA) | - | 2.60% | 2.79% | 2.74% | 2.42% | 2.23% |
Return on Invested Capital (ROIC) | 10.12% | 10.55% | 10.28% | 10.20% | 11.19% | 16.28% |
Return on Capital Employed (ROCE) | 22.50% | 23.00% | 29.00% | 28.30% | 24.70% | 23.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.66% | 2.19% | - | - | - | - |
FCF Yield | 12.13% | 5.42% | - | - | - | - |
Dividend Yield | 1.08% | 0.69% | - | - | - | - |
Payout Ratio | 40.13% | 46.79% | 66.53% | 68.06% | 81.68% | 89.32% |
Buyback Yield / Dilution | -12.67% | -6.46% | 0.05% | -0.35% | -0.14% | -0.10% |
Total Shareholder Return | -11.59% | -5.76% | 0.05% | -0.35% | -0.14% | -0.10% |